Zurich-based Memo Therapeutics secures €26 million Series C to speed up clinical development for renal transplant patients

Published on November 2, 2023

Memo Therapeutics (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced the closing of a €26 million Series C financing led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group, Fresenius Medical Care Ventures and Red Alpine joined in the round. MTx will use the proceeds to…

This content is for members only. Visit the site and log in/register to read.

The post Zurich-based Memo Therapeutics secures €26 million Series C to speed up clinical development for renal transplant patients appeared first on EU-Startups.

Continue reading on website
Other news

London-based insurtech Eleos raises €700k pre-seed to make income protection insurance accessible for all

November 2, 2023
Eleos, a UK-based insurtech, has secured a €700k pre-seed funding round backed by Indico Capital Partners, APX, Fuel Ventures, and Magic Fund, to make life and income protection insurance accessible for all. Eleos works in partnership with several popular brands, mostly other fintechs, to embed income protection insurance and life cover into their online journeys…. This content is for members only

Bullish or Bearish -- Analyzing 3 Energy Stocks

November 2, 2023
The energy sector is poised for significant expansion, propelled by escalating crude oil prices. Given this backdrop, let’s analyze the energy stocks Suncor Energy (SU), Marathon Petroleum Corporation (MPC), and...